Biotech | March 11, 2022
Emmes acquires Casimir, its fourth major acquisition
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
Colchicine tablets are used for the treatment and prevention of gout. It reduces inflammation which causes pain, swelling and other symptoms of gout
The RI investment comes on the back of three other recently completed transactions in Malaysia and Singapore in the last two months
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
It has blended 36 important ingredients for a woman’s health, which has a mix of natural extracts, amino acids, multivitamins and minerals
It is also setting up laboratories in West Bengal, Assam, Bihar, Jharkhand and Orissa to comprehensively cater to the East India region
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
Subscribe To Our Newsletter & Stay Updated
